Hematopoietic progenitor cell mobilization

Hematopoietic progenitor cell mobilization is a clinically critical process in which hematopoietic stem and progenitor cells are recruited from the bone marrow to the peripheral blood. This process is leveraged to harvest stem cells for transplantation, particularly in the treatment of hematologic malignancies. Mobilization can be induced pharmacologically by agents such as G-CSF, plerixafor, or chemotherapeutic drugs, which alter interactions in the bone marrow microenvironment, disrupt retention signals (e.g., SDF-1/CXCR4 axis), and trigger the release of progenitor cells into circulation. Mobilization efficiency varies among patients and is affected by multiple genetic and pharmacologic factors. Mechanistic targets within the mobilization process (such as CXCR4, SDF-1, G-CSF receptor) are therapeutically actionable, but the process name itself is not a direct therapeutic target[1][3][4][5][6].

Other names

Hematopoietic stem cell mobilizationHSC mobilizationMobilization of hematopoietic progenitor cells

Drugs that modulate this process work by altering bone marrow niche signaling, disrupting retention factors, or activating proteases: G-CSF induces proliferation and egress of progenitors via neutrophil-mediated proteolysis and downregulation of retention signals[1][3]. CXCR4 antagonists (plerixafor/AMD3100) block retention by SDF-1/CXCR4 signaling, resulting in cell release[6]. Chemokines like IL-8, GRO-β activate neutrophils and matrix metalloproteinases (MMP-9) to cleave adhesion molecules and release progenitors[1][5].